Genmab A GMAB
NASDAQ GMAB
$39.57 +0.50 (+1.28%)
At close: Oct 21, 2026 · 4:00 PM EDT

Genmab A (GMAB) Work In Process (2025)

Updated

Genmab A (GMAB) reported Work In Process of $1.13 billion for the quarter ended Dec 31, 2025.

Analysis

Genmab A (GMAB) Work In Process (2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Genmab A 2.56 Bn -2.81 Bn 1.07 Bn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 1.13 Bn
API Access

Genmab A Work In Process API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=work-in-process&ticker=GMAB&period=max&api_key=YOUR_API_KEY